IPO

Anthem Biosciences Limited IPO

Mainboard

Biotechnology

Listed On: Jul 21, 2025 at ₹ 723.05(NSE)

₹ 14820 /26 Shares

Check Allotment

14 Jul, 2025

Open Date

16 Jul, 2025

Close Date

17 Jul, 2025

Allotment Date

21 Jul, 2025

Listing Date
Price Summary

Last Closing

800.90 (40.51%)

52 Week High

873.50

52 Week Low

701.90

Last Update

10-Oct-2025 3:30 PM
Anthem Biosciences IPO Issue Details
  • Issue Price ₹540-570 per equity share
  • Face Value ₹2 Per Equity Share
  • Total Issue Size 5,95,61,404 shares(aggregating up to ₹3395 crore)
  • Offer For Sale 5,95,61,404 shares(aggregating up to ₹3395 crore)
  • Listing at BSE, NSE
  • List Price 723.05(NSE)
  • Listing Date 2025-07-21
  • Lead Manager Jm Financial Limited
    Citigroup Global Markets India Private Limited
    J.P. Morgan India Private Limited
    Nomura Financial Advisory And Securities (India) Pvt Ltd
  • Registrar Kfin Technologies Limited
Market Lot Size

Investors can bid for a minimum of 26 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

ApplicationLotsSharesAmount
Retail (min)126₹14,820
Retail(max)13338₹1,92,660
SHNI(min) 14364₹2,07,480
SHNI(max) 671,742₹9,92,940
BHNI(min) 681,768₹10,07,760
Anthem Biosciences IPO Reservation

Anthem Biosciences IPO offers total 5,95,75,319 shares. Out of which 1,18,83,333 (19.95%) allocated to QIB, 89,12,500 (14.96%) allocated to NII,2,07,95,834 (34.91%) allocated to RII, 1,58,653 (0.27%) allocated to employees and 1,78,24,999 (29.92%) allocated to Anchor investors.

Investor CategoryShares OfferedMaximum Allottees
Anchor Investor Shares Offered1,78,24,999 (29.92%)
QIB Shares Offered1,18,83,333 (19.95%)
NII (HNI) Shares Offered89,12,500 (14.96%)
bNII < ₹10L59,41,667 (9.97%)
sNII < ₹10L29,70,833 (4.99%)
Retail Shares Offered2,07,95,834 (34.91%)
Employee Shares Offered1,58,653 (0.27%)
Total Shares Offered5,95,75,319 (100%)
Anthem Biosciences IPO Documents
DRHP
RHP
ANCHOR
Anthem Biosciences IPO Details


Anthem Biosciences IPO is a book-built issue of ₹3395 crores, The total issue size is ₹3395 crores. The IPO of Anthem Biosciences is priced at ₹540-570 per equity share, which has a face value of ₹2 Per Equity Share each, IPO bidding starts from Jul 14, 2025 and ends on Jul 16, 2025. The allotment for Anthem Biosciences IPO will be finalized on Jul 17, 2025. Anthem Biosciences IPO will be listed on BSE, NSE, with a tentative listing date fixed as Jul 21, 2025. The company shall list its equity shares on the BSE, NSE. Kfin Technologies Limited is the registrar of the issue.

Retail investors can bid for a minimum of 26 shares, extendable to 14,820. S-HNIs will be able to bid for 364 shares at ₹2,07,480, while B-HNIs can also apply for a bid of 1,768 shares at ₹10,07,760. The book-running lead manager for the IPO is/are Jm Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd.

The total issue ₹3395 crore and having Offer for Sale (OFS) of 5,95,61,404 shares to mop up ₹3395 crore.

The Anthem Biosciences IPO sets its price band at 540-570 for each share. A single application for Anthem Biosciences Limited IPO must contain at least 26 shares. Sentiment investors need to invest a minimum of 26 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,820 In order to participate in the sNII, investors must purchase at least 14 lots of 364 shares for ₹2,07,480, while the bNII requires 68 lots of 1,768 shares for an investment of ₹10,07,760.

Read More
Anthem Biosciences IPO Subscription Analysis And Details
Retail
5.61x
QIB
182.65x
NII
42.35x
bNII
48.94x
sNII
29.17x
Total
63.85x
As onQIBNII
bNII   sNII		RetailTotal
Shares Offered / Reserved2,97,08,33389,12,500
59,41,667    29,70,833		2,07,95,8334,17,50,321
Day 1 14-07-25 05:00 PM
0.37 x1.55
1.37 x   1.92 x		0.58 x0.73 x
Day 2 15-07-25 05:00 PM
0.59 x9.72
9.87 x   9.41 x		2.08 x3.29 x
Day 3 16-07-25 05:00 PM
182.65 x42.35
48.94 x   29.17 x		5.61 x63.85 x
Total No of Applications
37,86,610
Subscription on the basis of Applications
Retail:4.5x BHNI:10x SHNI:29.0x
Anthem Biosciences Valuations
EPS Pre IPO ₹8.07/-
EPS Post IPO ₹8.07/-
P/E Pre IPO 70.62
P/E Post IPO 70.62
ROE 20.82%
ROCE 26.88%
Debt/Equity 0.05
RoNW 20.82%
PAT Margin 23.38%
Price to Book Value 13.23
Anthem Biosciences Company Financials
In Crs.
In Cr.
31-Mar-2531-Mar-2431-Mar-23
Assets2,807.582,398.112,014.46
Revenue1,930.291,483.071,133.99
Profit After Tax451.26367.31385.19
Net Worth2,409.861,924.661,740.67
Reserves & Surplus2,298.051,815.391,628.88
Total Borrowing108.95232.53125.06
About Anthem Biosciences Company

Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.

The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.

The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).

As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.

As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.

Read More
Anthem Biosciences - Promoter(s)

Ajay Bhardwaj

Ganesh Sambasivam

K Ravindra Chandrappa

Ishaan Bhardwaj

Pre Issue Share Holding : 77.23%

Post Issue Share Holding : 74.68%

Anthem Biosciences IPO - Issue Objectives
1

The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

Anthem Biosciences IPO - Anchor Investors

Anthem Biosciences IPO: Institutional buyers select Rs 1,016 crore worth of shares through anchor book.

World marquee investors such as Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, Optimix Wholesale Global Emerging Markets Share Trust, PineBridge Global Funds, and Societe Generale acquired the pharma firm's shares through anchor book.

Most asset management firms such as HDFC Mutual Fund, ICICI Prudential AMC, Kotak Mahindra Trustee, Nippon Life India Trustee, Aditya Birla Sun Life AMC, Axis Mutual Fund, Whiteoak Capital Mutual Fund, Franklin, Mirae Asset, UTI MF, Motilal Oswal MF, Quant Mutual Fund, Edelweiss Trusteeship, and Bandhan Mutual Fund also invested the lion's share of money (approximately Rs 604.4 crore) in to Anthem Biosciences through anchor book.

Anthem Biosciences IPO - Peers Comparison
Company NameEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Anthem Biosciences Limited8.078.0743.1N/A20.82N/AConsolidated
Syngene International Ltd12.3512.34117.4251.5411.056.21Consolidated
Sai Life Sciences Limited8.838.61102.1292.1810.967.45Consolidated
Cohance Lifesciences Limited10.5210.4572.3197.2913.6114.11Consolidated
DIVI'S LABORATORIES Limited82.5382.53564.8783.2215.3510.24Consolidated

Notes:

  1. The P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on BSE Limited ("BSE") as on 18 December, 2024 divided by the diluted earnings per share for the Fiscal ended March 31, 2024.
  2. Return on Net Worth (%) = Ratio of Profit /(loss) for the year attributable to owners of the company for the Fiscal to NetWorth as of the last day of the relevant Fiscal. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non-controlling interest.
  3. Net Asset Value per Equity Share = Net worth / Weighted average number of Equity Shares outstanding during the year. Net Worth means sum of equity share capital and other equity as of the last day of relevant fiscal and excludes non-controlling interest.
Strength
Fastest Indian CRDMO to cross ₹10,000 million revenue in 14 years.
Offers integrated CRDMO services across both small molecules and biologics.
Serves diverse global clients including Bayer AG and emerging biotech.
Operating India’s largest fermentation capacity of 142 kL as of Sep 2024
Weakness
CRDMO services contributed 81.13% revenue; demand decline may hurt.
Top 10 customers contributed 76.75% revenue; loss impacts business.
Regulatory non-compliance may disrupt exports, approvals, and customer confidence.
Underused capacity and poor forecasts could hurt future performance.
Contact Details

Anthem Biosciences

No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099

+91 080 6672 400

investors.abl@anthembio.com

https://www.anthembio.com/

Registrar Contact Details

Kfin Technologies Limited

04067162222, 04079611000

anthem.ipo@kfintech.com

https://kosmic.kfintech.com/ipostatus/